Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.7 EUR | +2.76% | -1.58% | +15.18% |
Apr. 22 | SCHOTT PHARMA : Jefferies remains Neutral | ZD |
Apr. 11 | Gerresheimer very weak - Certain uncertainties about outlook | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 38.67 and 30.95 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.18% | 6.26B | - | ||
-4.66% | 183B | C+ | ||
-1.01% | 108B | C | ||
-4.20% | 67.51B | A | ||
+2.68% | 50.67B | B- | ||
+9.12% | 44.7B | B- | ||
+3.40% | 40.95B | B+ | ||
+4.13% | 26.71B | A- | ||
+3.31% | 26.8B | B | ||
+13.63% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1SXP Stock
- Ratings SCHOTT Pharma AG & Co. KGaA